Aripiprazole for the maintenance treatment of bipolar I disorder: A review

Clinical Therapeutics

Volumn 32, Issue SUPPL. 1, 2010, Pages

  McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

bipolar disorder; maintenance; metabolic syndrome; obesity

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; LITHIUM; LORAZEPAM; PLACEBO;

AKATHISIA; ANXIETY; BIPOLAR I DISORDER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; MAINTENANCE THERAPY; MUSCLE HYPERTONIA; NAUSEA; NERVOUSNESS; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; LITHIUM; METABOLIC DISEASES; OBESITY; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 75349091659     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.022     Document Type: Review

References (40)

1. McIntyre R.S., and Konarski J.Z. Bipolar disorder: A national health concern. CNS Spectr. 9 Suppl 12 (2004) 6-15
2. Kessler R.C., Akiskal H.S., Ames M., et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry 163 (2006) 1561-1568
3. Hirschfeld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 64 (2003) 53-59
4. Zimmerman M., Ruggero C.J., Chelminski I., and Young D. Is bipolar disorder overdiagnosed?. J Clin Psychiatry 69 (2008) 935-940
5. Perlis R.H., Ostacher M.J., Patel J.K., et al. Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 163 (2006) 217-224
6. Tohen M., Bowden C.L., Calabrese J.R., et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry 189 (2006) 515-519
7. McIntyre R.S., Soczynska J.K., Beyer J.L., et al. Medical comorbidity in bipolar disorder: Re-prioritizing unmet needs. Curr Opin Psychiatry 20 (2007) 406-416
8. McIntyre R.S., Konarski J.Z., Soczynska J.K., et al. Medical comorbidity in bipolar disorder: Implications for functional outcomes and health service utilization. Psychiatr Serv. 57 (2006) 1140-1144
9. Vuksan-Cusa B., Marcinko D., Nad S., and Jakovljević M. Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry 33 (2009) 109-112
10. Richter N., Juckel G., and Assion H.J. Metabolic syndrome: A follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 260 (2010) 41-49
11. Kemp DE, Calabrese JR, Tran QV, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder. J Clin Psychiatry. In press.
12. Garcia-Portilla M.P., Saiz P.A., Bascaran M.T., et al., General Health Status in Bipolar Disorder Collaborative Group. Cardiovascular risk in patients with bipolar disorder. J Affect Disord. 115 (2009) 302-308
13. Garcia-Portilla M.P., Saiz P.A., Benabarre A., et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 106 (2008) 197-201
14. van Winkel R., De Hert M., Van Eyck D., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 10 (2008) 342-348
15. Fagiolini A., Frank E., Turkin S., et al. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 69 (2008) 678-679
16. Cardenas J., Frye M.A., Marusak S.L., et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 106 (2008) 91-97
17. Salvi V., Albert U., Chiarle A., et al. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 30 (2008) 318-323
18. McIntyre R.S., Soczynska J.K., Konarski J.Z., et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"?. Ann Clin Psychiatry. 19 (2007) 257-264
19. Taylor V., and MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry 67 (2006) 1034-1041
20. McIntyre R.S., and Konarski J.Z. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 Suppl 3 (2005) 28-36
21. McIntyre R.S., McCann S.M., and Kennedy S.H. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46 (2001) 273-281
22. McIntyre R.S., Mancini D.A., Pearce M.M., et al. Mood and psychotic disorders and type 2 diabetes: A metabolic triad. Can J Diab. 29 (2005) 122-132
23. McIntyre R.S. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 63 Suppl 3 (2002) 15-20
24. Keck Jr. P.E., Calabrese J.R., McQuade R.D., et al., Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67 (2004) 626-637
25. Keck Jr. P.E., Calabrese J.R., McIntyre R.S., et al., Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, doubleblind study versus placebo. J Clin Psychiatry 68 (2007) 1480-1491
26. Keck P.E., Orsulak P.J., Cutler A.J., et al., CN138-135 Study Group. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placeboand lithium-controlled study. J Affect Disord. 112 (2009) 36-49
27. McIntyre R.S., McElroy S., Pikalov A., et al. Metabolic effects of long-term treatment of patients with bipolar disorder with either lithium or aripiprazole. Poster presented at: 49th Annual Meeting of the NCDEU. Hollywood, Fla. (June 29-July 2, 2009)
28. Bowden C.L., Calabrese J.R., Sachs G., et al., Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder [published correction appears in Arch Gen Psychiatry. 2004;61:680]. Arch Gen Psychiatry 60 (2003) 392-400
29. Tohen M., Calabrese J.R., Sachs G.S., et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163 (2006) 247-256
30. Marcus R.N., McQuade R.D., Carson W.H., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28 (2008) 156-165
31. Trivedi M.H., Thase M.E., Fava M., et al. Adjunctive aripiprazole in major depressive disorder: Analysis of efficacy and safety in patients with anxious and atypical features. Clin Psychiatry 69 (2008) 1928-1936
32. Berman R.M., Marcus R.N., Swanink R., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68 (2007) 843-853
33. Correll C.U., Manu P., Olshanskiy V., et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302 (2009) 1765-1773
34. Bowden C.L., Calabrese J.R., Wallin B.A., et al. Illness characteristics of patients in clinical drug studies of mania. Psychopharmacol Bull. 31 (1995) 103-109
35. McIntyre R.S., Rasgon N.L., Kemp D.E., et al. Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap. Curr Diab Rep. 9 (2009) 51-59
36. McIntyre R.S. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 70 (2009) e17
37. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy, and research challenges. J Clin Psychiatry 69 (2008) 514-519
38. McIntyre R.S., McElroy S.L., Konarski J.Z., et al. Substance use disorders and overweight/obesity in bipolar l disorder: Prelimary evidence for competing addictions. J Clin Psychiatry 68 (2007) 1352-1357
39. Ng F., Mammen O.K., Wilting I., et al., lnternational Society for Bipolar Disorders. The International Society for Bipolar Disorders (lSBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 11 (2009) 559-595
40. Kim B., Kim S., McIntyre R.S., et al. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Invest. 6 (2009) 78-84